{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:40:22Z","timestamp":1794336022750,"version":"4.9.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.1080\/14787210.2023.2203913","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:46:39Z","timestamp":1681731999000},"page":"565-570","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options"],"prefix":"10.1080","volume":"21","author":[{"given":"Jessica","family":"Tuan","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale AIDS Program, Yale School of Medicine,New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA"},{"name":"Yale AIDS Program, Yale School of Medicine,New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"cit0001","unstructured":"Sunlenca (lenacapavir) Receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. Gilead, Dec 22, 2022. Accessed Feb 9, 2023. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/12\/sunlenca-lenacapavir-receives-fda-approval-as-a-firstinclass-twiceyearly-treatment-option-for-people-living-with-multidrug-resistant-hiv"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-023-00005-z"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2204376"},{"key":"cit0005","unstructured":"Drug Database: Lenacapavir. Clinicalinfo.hiv.gov, Jan 4, 2023. Accessed Feb 9, 2023. https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/lenacapavir-hiv-prevention\/health-professional"},{"key":"cit0006","unstructured":"Sunlenca. Annex I: summary of product characteristics. Europeans Medicines Agency, 2022. Accessed Feb 9, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sunlenca-epar-product-information_en.pdf"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02057-20"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000713"},{"key":"cit0009","unstructured":"Fact Sheet LP, University of Liverpool, Oct 2022. Accessed Feb 9, 2023. https:\/\/liverpool-hiv-hep.s3.amazonaws.com\/prescribing_resources\/pdfs\/000\/000\/229\/original\/HIV_FactSheet_LEN_2022_Oct.pdf?1665666788"},{"key":"cit0010","unstructured":"Sunlenca 464 mg solution for injection. emc, Oct 2022. Accessed Feb 9, 2023. https:\/\/www.medicines.org.uk\/emc\/product\/14102\/smpchttps:\/\/www.medicines.org.uk\/emc\/product\/14102\/smpc"},{"key":"cit0011","unstructured":"Sunlenca (lenacapavir) Prescribing Information. FDA, 2022. Accessed Feb 9 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215973s000lbl.pdf"},{"key":"cit0012","unstructured":"Jogiraju V, Graham H, West S, et al. Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2\/3 regimen. AIDS 2022. Accessed Feb 9, 2023. https:\/\/programme.aids2022.org\/Abstract\/Abstract\/?abstractid=5490"},{"key":"cit0013","volume-title":"CROI Conference, March 2020","author":"Daar E"},{"issue":"2","key":"cit0014","volume":"9","author":"Ogbuagu O","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"cit0015","unstructured":"FDA lifts clinical hold on investigational lenacapavir for the treatment and prevention of HIV. Gilead, May 16, 2022. Accessed Feb 9, 2023. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2022\/5\/fda-lifts-clinical-hold-on-investigational-lenacapavir-for-the-treatment-and-prevention-of-hiv"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.108"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac388"},{"key":"cit0018","volume-title":"26th Conference on Retroviruses and Opportunistic Infections","author":"Yant SR","year":"2019"},{"key":"cit0019","unstructured":"Study to compare bictegravir\/lenacapavir versus current therapy in people with HIV-1 who are successfully treated with a complicated regimen. Clinicaltrials.gov, 2023. Accessed Feb 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05502341"},{"key":"cit0020","unstructured":"Study to evaluate the safety and efficacy of GS-5423 and GS-2872 in combination with lenacapavir (GS-6207) in virologically suppressed adults with HIV-1 infection. Clinicaltrials.gov, 2022. Accessed Feb 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/history\/NCT04811040?V_2=View"},{"key":"cit0021","unstructured":"Study to assess safety and efficacy of lenacapavir and emtricitabine\/tenofovir alafenamide for pre-exposure prophylaxis in adolescent girls and young women at risk of hiv infection (PURPOSE 1). Clinicaltrials.gov, Mar 2023. Accessed Feb 9, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04994509"},{"key":"cit0022","unstructured":"PURPOSE: Prevention with PURPOSE. Purposestudies.com, 2022. Accessed Feb 9 2023. https:\/\/www.purposestudies.com\/#:~:text=The%20PURPOSE%20trials%20will%20evaluate-exposure%20prophylaxis%20.PrEP"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2023.2203913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:41:22Z","timestamp":1684849282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2023.2203913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,3]]}},"alternative-id":["10.1080\/14787210.2023.2203913"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2023.2203913","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}